Quantum Biopharma (QNTM) reported a 2024 net loss of $14.9 million, narrowing from the loss of $18.2 million a year earlier.
Cash and cash equivalents were $12.1 million as of December 31, compared with $11.1 million a year earlier, the company said Friday in a statement.
A "strong balance sheet and overall progress" enabled the company to remove its "material uncertainty related to going concern" designation, according to the statement. "Management believes there is sufficient cash on hand to sustain basic operations beyond January 2027."
The company's shares jumped 35% in recent Friday trading.
Price: 11.28, Change: +2.90, Percent Change: +34.59
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。